First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial

摘要

In a randomized study of pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) or gefitinib monotherapy (G) in East Asian never-smoker patients with advanced nonsquamous non-small-cell lung cancer, the quality of life symptoms were more favorable in the G group than in the PC/G group. In patients with wild-type epidermal growth factor receptor, tumor-related symptoms appeared to improve more with PC/G than with G.